ONCO stock forecast, quote, news & analysis
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology... Show more
Why Onconetix (ONCO) Stock Is Down -58% in the Last 30 Days
Key Takeaways
- Onconetix (ONCO) fell roughly 58% over the trailing 30 days, from a late-September closing level near $1.03 to about $0.43.
- The decline largely reflects the reversal of a sharp, late-September speculative surge tied to progress on the pending Realbotix acquisition.
- The all-stock Realbotix deal would leave the seller owning 75%–90% of the combined company, a structure implying meaningful dilution for existing shareholders.
- Micro-cap liquidity, elevated short interest, and continued operating losses have amplified the stock's downside volatility.
- Over the trailing quarter, the stock is also lower, down roughly 48% from its late-July level.
- Onconetix's core asset remains Proclarix, an EU-approved prostate-cancer diagnostic licensed to Labcorp (LH) for U.S. commercialization.
- For more detail on valuation and expectations, explore Onconetix's Price Targets, Earnings, and Forecast pages.
- To track momentum-driven setups across the broader market, explore Trending AI Robots.
Onconetix (ONCO) Company Overview and Market Position
Onconetix, Inc. is a commercial-stage biotechnology company focused on men's health and oncology. Formerly known as Blue Water Biotech, the company adopted its current name in December 2023 and is headquartered in Cincinnati, Ohio. Its flagship product is Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer that is approved for sale in the European Union under the In Vitro Diagnostic Regulation (IVDR). Onconetix holds a license agreement with Laboratory Corporation of America (LH) to develop and commercialize Proclarix as a lab-developed test in the United States, as well as a license with Immunovia AB for the PancreaSure test. In February 2026, the company announced an all-stock agreement to acquire Realbotix LLC, a developer of AI-powered humanoid robots, marking a strategic pivot toward embodied AI and robotics.
Onconetix (ONCO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ONCO declined approximately 58%, moving from a closing level near $1.03 in late September to roughly $0.43. The move was not a straight line: the stock experienced an intense, high-volume surge in late September before reversing sharply through October, giving back nearly all of those gains.
The broader multi-month picture tells a similar story of decline punctuated by sharp, short-lived rallies. Over the trailing quarter, the stock fell roughly 48% from its late-July level of about $0.83. Throughout this period, trading has been characterized by outsized volume spikes, wide intraday ranges, and rapid mean reversion, a pattern consistent with a thinly traded micro-cap stock that is highly sensitive to news flow around its pending transaction.
What Drove ONCO Stock Price in the Last 30 Days
The 30-day move was dominated by the reversal of a late-September speculative rally tied to the pending Realbotix acquisition. In late September, shares spiked on extraordinary volume, briefly trading above $1.00, as investors reacted to a series of filings and announcements around the transaction, including proxy materials and a strategic bridge-financing facility. The company announced a Grid Promissory Note providing up to $5 million to support Realbotix's working capital, with an initial $2.5 million advance funded in September.
That speculative bid faded quickly. Several structural factors weighed on sentiment: the all-stock structure of the deal, under which the seller is expected to own 75%–90% of the combined company, implies substantial dilution for existing ONCO shareholders. Meanwhile, the company continues to report operating losses, and its thin float and elevated short interest make the stock vulnerable to rapid downside when buying momentum stalls. The result was a steady retreat through October, punctuated by brief, high-volume bounces that failed to hold.
What Drove ONCO Stock Performance Over the Last Quarter
Across the trailing quarter, the dominant narrative has been Onconetix's strategic pivot from a pure-play oncology diagnostic company toward AI-powered humanoid robotics through the Realbotix acquisition. Announced in February 2026 and targeted to close in the second half of 2026, the transaction has driven repeated waves of speculative interest, particularly as the company highlighted milestones such as Realbotix's delivery of robots to enterprise clients.
However, that enthusiasm has been offset by persistent concerns about dilution, integration risk, and the company's financial position. Onconetix advanced additional bridge financing to Realbotix through the quarter, bringing total principal advanced to $3 million by late October, underscoring the working-capital needs of the pending combination. The net effect has been a downward-trending but highly volatile stock, with each rally giving way to renewed selling pressure.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading bots. While Tickeron offers hundreds of AI trading bots that monitor thousands of tickers across the market, only the most relevant and best-performing bots appear in this featured section. These bots vary considerably in strategy, trading timeframe, and performance metrics, ranging from short-term momentum systems to longer-horizon approaches. The curated view is designed to help traders quickly identify strategies that have recently demonstrated strength, while allowing users to evaluate each bot's methodology and track record before engaging. Traders interested in data-driven, rules-based approaches can explore Trending AI Robots to review the currently featured strategies.
ONCO Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape ONCO's path going forward. First, the shareholder vote and closing of the Realbotix acquisition remain the central catalyst; completion is subject to Onconetix shareholder approval, regulatory clearances, and a requirement for a minimum net-cash position at closing. Second, the degree of dilution resulting from the all-stock structure will be a key valuation consideration for current holders. Third, progress on Proclarix's U.S. commercialization through the Labcorp license represents the company's core biotech revenue opportunity. Finally, broader investor sentiment toward AI and humanoid-robotics stocks, combined with Onconetix's own cash runway and operating losses, will continue to influence volatility in this micro-cap name. Investors should monitor these developments carefully, as the stock remains highly sensitive to both fundamental and speculative forces.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ONCO's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for ONCO moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +21.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCO advanced for three days, in 142 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONCO as a result. In 76 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ONCO turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In 33 of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ONCO moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ONCO crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ONCO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONCO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.260) is normal, around the industry mean (3.498). P/E Ratio (0.009) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.598) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology